Covid, AstraZeneca withdraws the authorization of the vaccine in the EU. «There was no longer any question»

Covid, AstraZeneca withdraws the authorization of the vaccine in the EU. This is confirmed by the Anglo-Swedish company itself: «Given the quantity of available and effective vaccines for the new variants of Covid-19, there was no longer any demand for the Vaxzevria vaccine which consequently was no longer produced or distributed. Therefore, we do not foresee future demand for the product, we read in a note sent to Adnkronos Salute. «AstraZeneca has therefore decided to withdraw the marketing authorization for Vaxzevria within the EU». specifies the company.

The decision

AstraZeneca’s decision comes days after it admitted in court documents during legal proceedings in London that its Covid vaccine may cause thrombosis as a rare side effect. The pharmaceutical giant is being sued in a class action over its vaccine developed with the University of Oxford. Lawyers argue that the drug produced a side effect that had a devastating effect on a small number of families. AstraZeneca disputes the allegations but accepted, in a legal document submitted to London’s High Court in February, that its Covid vaccine “may, in very rare cases, cause TTS”, a thrombosis with thrombocytopenia syndrome. Fifty-one cases have been lodged in the High Court, with victims and relatives seeking damages worth an estimated up to £100 million. The first case was filed last year by father-of-two Jamie Scott, who was left with a permanent brain injury after developing a blood clot and brain haemorrhage after receiving the vaccine in April 2021.

The letter

In a response letter sent in May 2023, AstraZeneca told Scott’s lawyers that it did not accept that TTS was “caused by the vaccine at a generic level”. However, “it is accepted that the AZ vaccine can, in very rare cases, cause Tts. The causal mechanism is not known” and “furthermore, Tts can occur even in the absence of the AZ vaccine (or any vaccine). causality in each individual case will be tested by experts.” AstraZeneca underlined in any case that the product information relating to the vaccine was updated in April 2021, with the approval of the UK regulator, to include “the possibility that the AstraZeneca-Oxford vaccine could, in very rare cases, be a trigger for TTS”.

© ALL RIGHTS RESERVED

Read the full article at
The messenger